RxDoctor Payments Data

Bryan Lazaro

Psychiatric/Mental Health · Scottsdale, AZNPI 1912458845

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $58,025 of the $61,277 with a category attached, or 94.7%. AbbVie accounts for 98.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $29,434 and has fallen 99.8% since, to $54 in 2025. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$61,277in general payments, 2019–2025

Across 106 payments — averaging $578.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$60K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$589
  • Otsuka America Pharmaceutical, Inc.$250
  • Axsome Therapeutics, Inc.$54
  • Johnson & Johnson$42

What the payments were for

  • Consulting fees$4501%
  • Speaking & faculty fees$58,02595%
  • Travel & lodging$1,6443%
  • Food & beverage$1,1592%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,277 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$14,060
Medicare patients
15
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl24$36,362
RexultiBrexpiprazole13$17,515
Lurasidone Hcl11$3,164
Methylphenidate ErMethylphenidate Hcl31$2,843
Bupropion XlBupropion Hcl56$1,322
Quetiapine Fumarate47$1,304
Vilazodone Hcl12$1,222
Venlafaxine Hcl ErVenlafaxine Hcl41$788
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine40$763
Aripiprazole25$491
Duloxetine Hcl25$439
Guanfacine Hcl ErGuanfacine Hcl13$391
Lamotrigine43$390
Olanzapine23$385
Gabapentin25$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$60,342$36,36224 claims
Otsuka America Pharmaceutical, Inc.Rexulti$250$17,51513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →